InsidersTradesSigma
Track the Biota Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 9 February 2016 (Acquisition). Among the most active insiders: COLONNESE MARK P. Every trade is openly available.
Analysts rate Biota Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Biota Pharmaceuticals, Inc. is a company focused on developing antiviral treatments. It is listed on NASDAQ under the ticker XNAS.